carrito Compra

(0 Productos)

Gastos de envío GRATIS

Solo para España


COMPREHENSIVE DERMATOLOGIC DRUG THERAPY (Book + eBook)

COMPREHENSIVE DERMATOLOGIC DRUG THERAPY (Book + eBook)-9780323612111
  1. Autor:

    Wolverton

  2. Isbn:

    9780323612111

  3. Páginas:

    1024

  4. Año:

    2020

  5. Edición:

    4

  6. Idioma:

    Ingles

  7. Disponibilidad:

    De 7 a 10 Días

Precio s/iva:

135.00 €

128,25  €
Volver

DESCRIPTION:
Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you""re likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today""s full spectrum of topical, intralesional, and systemic drugs. You""ll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor.

Key Features:
- Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions.
- Covers the best uses for new biologic therapeutics.
- Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors.
- Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols.
- Features a highly detailed, disease-specific index, as well as purchase information for major drugs.
- Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book.
- Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

CONTENTS:
Part I: Introduction
1. Basic principles of pharmacology
2. Principles for maximizing the safety of dermatologic drug therapy
3. Polymorphisms : why individual drug responses vary
4. Adherence to drug therapy
Part II: Important Drug Regulatory Issues
5. The FDA drug approval process
6. Pharmacovigilance : verifying that drugs remain safe
7. Drugs taken off the market : important lessons learned
8. Medical decision making principles NEW
Part III: Systemic Drugs for Infectious Diseases
9. Systemic Antibacterial Agents
10. Systemic antifungal agents
11. Systemic antiviral agents
12. Systemic antiparasitic agents
Part IV: Systemic Immunomodulatory and Antiproliferative Drugs
13. Systemic corticosteroids
14. Methotrexate
15. Azathioprine
16. Mycophenolate
17. Cyclosporine
18. PDE-4 and JAK inhibitors NEW
19. Cytotoxic agents
20. Dapsone
21. Antimalarial agents
22. Systemic retinoids
Part V: Drugs Used in Conjunction with Ultraviolet or Visible Light
23. PUVA photochemotherapy and other phototherapy modalities
24. Extracorporeal photochemotherapy (photopheresis)
25. Photodynamic therapy
Part VI: Biological Therapeutics
26. Tumor necrosis factor (TNF) inhibitors
27. Interleukin 12/23 inhibitors - ustekinumab
28. Interleukin 17A inhibitors - secukinumab, ixekizumab, brodalumab NEW
29. Interleukin 23 inhibitors - guselkumab, tildrakizumab, rizankizumab NEW
30. Rituximab
31. Additional biological therapeutics - dupilumab, omalizumab, others NEW
Part VII: Miscellaneous Systemic Drugs
32. Antihistamines
33. Vasoactive and antiplatele t agents
34. Antiandrogens and androgen inhibitors
35. Psychotropic agents
36. Intravenous immunoglobulin therapy
37. Systemic anticancer agents : dermatologic indications and adverse events
38. Hedgehog pathway inhibitors - vismodegib, sonidegib NEW
39. Drugs for the skinternist
40. Miscellaneous systemic drugs
Part VIII: Topical Drugs for Infectious Diseases
41. Topical Antibacterial Agents
42. Topical antifungal agents
43. Topical and intralesional antiviral agents
44. Topical antiparasitic agents
Part IX: Topical Immunomodulatory and Antiproliferative Drugs
45. Topical corticosteroids
46. Topical retinoids
47. Topical and intralesional chemotherapeutic agents
48. Topical calcineurin inhibitors
49. Topical Vitamin D3
Part X: Miscellaneous Topical Drugs
50. Sunscreens
51. Therapeutic shampoos
52. a-Hydroxy acids
53. Chemical peels
54. Products for the care of chronic wounds
55. Agents used for treatment of hyperkeratosis
56. Irritants and allergens : When to suspect topical therapeutic agents
57. Miscellaneous topical agents
Part XI: Injectable and Mucosal Routes of Drug Administration
58. Local anesthetics
59. Injectable drugs for cosmetic indications
60. Botulinum toxin injections
61. Oral mucosal therapeutics
Part XII: Major Adverse Effects from Systemic Drugs
62. Hepatotoxicity of dermatologic drug therapy
63. Hematologic toxicity of drug therapy
64. Drug-induced malignancy
65. Dermatologic drugs during pregnancy and lactation
66. Drug interactions
67. Cutaneous drug reactions with systemic features
Part XIII: Special Pharmacology and Therapeutic Topics
68. Informed consent and risk management
69. Compounding in dermatology
70. Dermatologic drug therapy in children
Appendix I - Ten drugs of increasing importance to dermatology
Appendix II - Dapsone patient education and informed consent
Part I: Introduction
1. Basic principles of pharmacology
2. Principles for maximizing the safety of dermatologic drug therapy
3. Polymorphisms : why individual drug responses vary
4. Adherence to drug therapy
Part II: Important Drug Regulatory Issues
5. The FDA drug approval process
6. Pharmacovigilance : verifying that drugs remain safe
7. Drugs taken off the market : important lessons learned
8. Medical decision making principles NEW
Part III: Systemic Drugs for Infectious Diseases
9. Systemic Antibacterial Agents
10. Systemic antifungal agents
11. Systemic antiviral agents
12. Systemic antiparasitic agents
Part IV: Systemic Immunomodulatory and Antiproliferative Drugs
13. Systemic corticosteroids
14. Methotrexate
15. Azathioprine
16. Mycophenolate
17. Cyclosporine
18. PDE-4 and JAK inhibitors NEW
19. Cytotoxic agents
20. Dapsone
21. Antimalarial agents
22. Systemic retinoids
Part V: Drugs Used in Conjunction with Ultraviolet or Visible Light
23. PUVA photochemotherapy and other phototherapy modalities
24. Extracorporeal photochemotherapy (photopheresis)
25. Photodynamic therapy
Part VI: Biological Therapeutics
26. Tumor necrosis factor (TNF) inhibitors
27. Interleukin 12/23 inhibitors - ustekinumab
28. Interleukin 17A inhibitors - secukinumab, ixekizumab, brodalumab NEW
29. Interleukin 23 inhibitors - guselkumab, tildrakizumab, rizankizumab NEW
30. Rituximab
31. Additional biological therapeutics - dupilumab, omalizumab, others NEW
Part VII: Miscellaneous Systemic Drugs
32. Antihistamines
33. Vasoactive and antiplatele t agents
34. Antiandrogens and androgen inhibitors
35. Psychotropic agents
36. Intravenous immunoglobulin therapy
37. Systemic anticancer agents : dermatologic indications and adverse events
38. Hedgehog pathway inhibitors - vismodegib, sonidegib NEW
39. Drugs for the skinternist
40. Miscellaneous systemic drugs
Part VIII: Topical Drugs for Infectious Diseases
41. Topical Antibacterial Agents
42. Topical antifungal agents
43. Topical and intralesional antiviral agents
44. Topical antiparasitic agents
Part IX: Topical Immunomodulatory and Antiproliferative Drugs
45. Topical corticosteroids
46. Topical retinoids
47. Topical and intralesional chemotherapeutic agents
48. Topical calcineurin inhibitors
49. Topical Vitamin D3
Part X: Miscellaneous Topical Drugs
50. Sunscreens
51. Therapeutic shampoos
52. a-Hydroxy acids
53. Chemical peels
54. Products for the care of chronic wounds
55. Agents used for treatment of hyperkeratosis
56. Irritants and allergens : When to suspect topical therapeutic agents
57. Miscellaneous topical agents
Part XI: Injectable and Mucosal Routes of Drug Administration
58. Local anesthetics
59. Injectable drugs for cosmetic indications
60. Botulinum toxin injections
61. Oral mucosal therapeutics
Part XII: Major Adverse Effects from Systemic Drugs
62. Hepatotoxicity of dermatologic drug therapy
63. Hematologic toxicity of drug therapy
64. Drug-induced malignancy
65. Dermatologic drugs during pregnancy and lactation
66. Drug interactions
67. Cutaneous drug reactions with systemic features
Part XIII: Special Pharmacology and Therapeutic Topics
68. Informed consent and risk management
69. Compounding in dermatology
70. Dermatologic drug therapy in children
Appendix I - Ten drugs of increasing importance to dermatology
Appendix II - Dapsone patient education and informed consent

Author Information:
By Stephen E Wolverton, Professor of Clinical Dermatology Vice Chair of Clinical Affairs and Jashin J. Wu, MD, FAAD, Director of Dermatology Research, Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA



Libreria Médica Berri 2022 ®